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Abstract
DNA microarrays have the potential to classify tumors according to their transcriptome. Tissue 
microarrays (TMAs) facilitate the validation of biomarkers by offering a high-throughput 
approach to sample analysis. We reanalyzed a high profile breast cancer DNA microarray dataset 
containing 96 tumor samples using a powerful statistical approach, between group analyses. 
Among the genes we identified was centromere protein-F (CENP-F), a gene associated with poor 
prognosis. In a published follow-up breast cancer DNA microarray study, comprising 295 tumour 
samples, we found that CENP-F upregulation was significantly associated with worse overall 
survival (p < 0.001) and reduced metastasis-free survival (p < 0.001). To validate and expand upon 
these findings, we used 2 independent breast cancer patient cohorts represented on TMAs. CENP-
F protein expression was evaluated by immunohistochemistry in 91 primary breast cancer samples 
from cohort I and 289 samples from cohort II. CENP-F correlated with markers of aggressive 
tumor behavior including ER negativity and high tumor grade. In cohort I, CENP-F was 
significantly associated with markers of CIN including cyclin E, increased telomerase activity, c-
Myc amplification and aneuploidy. In cohort II, CENP-F correlated with VEGFR2, 
phosphorylated Ets-2 and Ki67, and in multivariate analysis, was an independent predictor of 
worse breast cancer-specific survival (p = 0.036) and overall survival (p = 0.040). In conclusion, 
we identified CENP-F as a biomarker associated with poor outcome in breast cancer and showed 
several novel associations of biological significance.
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In a study by van’t Veer et al. published in 2002, a 70-gene prognosis classifier was 
identified via DNA microarray analysis of primary breast cancer that could be used to 
predict metastatic potential.1 This work received considerable attention worldwide, and 
formed the basis for a clinical trial assessing the utility of DNA microarray technology in 
guiding treatment decisions for breast cancer patients.2 However, some concerns have been 
raised about the data analysis methods and sample distributions utilized for this study.3-5 To 
address such concerns, we reanalyzed this key DNA microarray dataset, validated our 
findings in 2 independent patient cohorts, and used tissue microarray (TMA) technology to 
explore biomarker associations with other known tumor variables. For re-analysis, we used 
the supervised method of BGA, which is based on carrying out an ordination (e.g. principal 
component analysis) of groups of samples rather than of individual samples. We previously 
demonstrated the successful application of BGA to DNA microarray data, and identified 
clinically important genes that were missed in previous analyses.6 In the present study, we 
trained and cross-validated a gene classifier which maximally discriminated between 
patients with a good or poor prognosis. CENP-F was among the genes highly expressed in 
breast tumors of patients with poor prognosis, a finding that we validated in a related DNA 
microarray dataset.5 Since little is known about the function of CENP-F in cancer, we 
examined its association with other known tumor parameters. Finally, we used 
immunohistochemistry on TMAs from 2 independent primary breast cancer cohorts to 
validate CENP-F protein expression as a prognostic marker, and identified coexpressed 
proteins that indicate a possible functional role of CENP-F in breast cancer.
Material and methods
Public DNA microarray datasets
Tumor samples and patient characteristics were described previously.1,5 The van de Vijver 
dataset,5 contained 61 patients with lymph node-negative disease from the original van’t 
Veer study.1
DNA microarray data analysis
For the van’t Veer dataset,1 the expression data arising from analysis of ~25,000 human 
genes in 78 samples was filtered according to the original criteria.1 In brief, genes were 
excluded if they did not display at least a 2-fold difference in expression and a p value of 
less than 0.01 in more than 3 samples. BGA, using Correspondence Analysis to ordinate the 
good and poor prognosis groups,6 was applied to the resulting dataset of ~5,000 genes and 
used to classify the remaining 19 test samples. The 96 pooled training and test samples were 
randomly recategorized into 77 training and 19 test samples. Sample 54 was removed from 
the analysis as it contained >20% missing values. The 96 samples were re-split 100 times 
and BGA performed at each iteration. The top 100 genes associated with good prognosis and 
the top 100 genes associated with poor prognosis were then selected. BGA was performed 
using the ADE4 module from Bioconductor (http://www.bioconductor.org). Analysis was 
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performed using the statistical package R (http://www.r-project.org); the relevant R scripts 
are available on request. Data was downloaded from http://microarray-pubs.stanford.edu/
wound_NKI/explore.html. For the van de Vijver dataset,5 CENP-F mRNA expression was 
categorized as negative/low, unchanged, or high expression relative to pooled cRNA from 
each patient sample, acting as reference cRNA. Tumor samples were classified according to 
CENP-F mRNA expression based on absolute expression analysis P values (alpha level of 
0.05), following the method of Moody et al.7
Patients and tumour samples for TMA analysis
Patients from the 2 independent primary breast cancer cohorts used in this study have been 
described previously.8 In brief, cohort I consisted of 114 patients diagnosed with primary 
invasive breast cancer in Northern Sweden during 1988–1991. Samples were available from 
91 patients for analysis of CENP-F expression.
Cohort II consisted of 512 consecutive breast cancer patients diagnosed at the Department of 
Pathology, Malmö University Hospital, Sweden during 1988–1992. Samples were available 
from 289 patients for analysis of CENP-F expression. The 289 tumor samples had a higher 
proportion of larger (p < 0.001), ER-negative (p < 0.001), high grade tumours (p < 0.001) 
and node-positive patients (p = 0.019), when compared with the 223 missing samples. There 
was no significant difference in patient age (p = 0.367), histological type (p = 0.494) or PR 
status (p = 0.204) between available and unavailable samples. Ethical approval was obtained 
for the use of human tissue samples for research from the Review Boards at Umeå and Lund 
universities, respectively.
Construction of TMAs and immunohistochemistry
TMAs were prepared separately for each cohort as previously described.9 The tissue was 
deparaffinised, rehydrated and microwave-treated for 10 min in citrate buffer (pH 6.0). For 
detection of CENP-F, we used a rabbit polyclonal antibody (Abcam, Cambridge, UK; ab5) 
at a dilution of 1:100. Antibody specificity was confirmed by comparing the 
immunohistochemical staining of cell lines with corresponding Western blot reactivity. 
Nuclear staining immunoreactivity was determined by estimating the percentage of 
distinctly positive tumor cell nuclei. Based on previous studies of CENP-F,10 we used a 10% 
cut-off point to categorise CENP-F expression, where 0–9% = “<10%”; and 10–100% = 
“≥10%”. The results were separately scored by 2 observers and results compared. Any 
discrepancies in scoring were rescored by both observers together and a consensus reached. 
Evaluation of Ki67, VEGF-A, VEGFR1, VEGFR2, p53, phospho-ERK 1/2 and phospho-
Ets-2 has been described elsewhere.8,11-13
Cell culture
The breast cancer cell lines T47D, BT474 and MDA-MB-231 and SK-BR3 were obtained 
from the European Collection of Cell Cultures, Wiltshire, UK. T47D, BT474 and MDA-
MB-231 cell lines were grown in DMEM (Sigma, MO) supplemented with 10% FCS 
(Invitrogen, CA), L-glutamine (2 μM), penicillin (50 IU/ml) and streptomycin sulphate (50 
μg/ml). SK-BR3 cells were grown in McCoy’s 5a Medium (Sigma, MO) supplemented with 
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10% FCS. Cells were maintained in humidified air with 5% CO2. Metaphase-arrested cells 
were obtained by incubating cells in the presence of nocodazole (1 μM) for 16 h.
Cell line array
The breast cancer cell lines T47D, SK-BR3, BT474 and MDA-MB-231 were used to 
optimize the anti-CENP-F antibody for immunohistochemical analysis. Cell lines were fixed 
in PFA for 30 min and resuspended in 70% ethanol overnight before being embedded in 
paraffin and arrayed.
Western blotting
Cultured cells were washed in 10 ml PBS, harvested and lysed in RIPA buffer containing 20 
mM Tris pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 1 mM 
EDTA, 0.1% SDS and protease inhibitor cocktail (Sigma, MO). Protein levels were 
determined using the bicinchoninic acid (BCA) method (Pierce, IL). Samples containing 30 
μg of protein were separated on a 3–8% Tris-acetate gel (Invitrogen, CA) by SDS-PAGE 
under reducing conditions. After electrophoresis, proteins were transferred to a 
polyvinylidene fluoride (PVDF) membrane, Immobilin P (Millipore, MA). Membranes were 
blocked in 5% non-fat milk for 1 h. CENP-F expression was detected using a rabbit 
polyclonal anti-human CENP-F antibody (1:1500, clone ab5 from Abcam). Membranes 
were washed and incubated for 1 h with horseradish peroxidase-conjugated anti-rabbit 
antibody (1:10,000; Promega, UK). Antigen-antibody complexes were detected using ECL 
Plus reagent (Amersham Biosciences, Buckinghamshire, UK). Expression of cyclin E was 
measured by Western blotting and densitometry and was described previously.11,14
TMA statistical analysis
The χ2 test for trend, Fisher’s exact and Mann–Whitney tests were used for comparison of 
CENP-F expression with all other known parameters. Kaplan–Meier plots were used for 
survival analysis and the curves compared using the log-rank test.15 Cox proportional 
hazards regression was used to estimate proportional hazard ratios and conduct multivariate 
analyses. All calculations were performed with SPSS v11.0 (SPSS, IL).
Results
Identification of alternative candidate biomarkers for primary breast cancer following 
reanalysis of DNA microarray data
When implementing BGA, we used an identical filter criterion set by van’t Veer et al. in 
their original analysis,1 which reduced the number of genes from 25,000 to just over 5,000. 
The original 78 training breast tumor samples were initially used to identify discriminating 
genes, and the 19 test samples used for validation of the identified genes. The classification 
accuracy we achieved was comparable to the original analysis,1 with 84% of the test set 
being ascribed to the correct prognosis group (data not shown).
To remove a possible training and test sample selection bias, we randomly recategorized 
patient breast tumor samples into training and test samples. By applying BGA iteratively, the 
classification accuracy ranged from 36 to 84% with a median classification accuracy of 68% 
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(Fig. 1). A discrimination score was calculated for each gene by averaging the contribution 
(or weight) of a gene in each BGA over 100 iterations. Thus, this approach should produce a 
more robust gene ranking, as genes with more discrimination power should re-occur more 
frequently at higher rankings. Each of the 5,000 genes was ranked according to its average 
BGA co-ordinate. Supplementary Tables SIa and SIb detail the top 100 genes associated 
with good prognosis and the top 100 genes associated with poor prognosis, respectively, 
identified using BGA. Genes were then categorised into gene ontology (GO) categories 
(Table SII and Figs. S1 and S2). Genes involved in the cell cycle (p ≤ 0.001) and movement/
motor activity (p ≤ 0.001) were significantly over-represented while genes involved in 
development (p ≤ 0.001), signal transduction (p≤ 0.001) and cell communication (p≤ 0.034) 
were significantly under-represented, in the poor prognosis group. Tables SIIIa and SIIIb 
detail the functional categories associated with each of the top 100 genes associated with 
good prognosis and the top 100 genes associated with poor prognosis.
Among the genes we identified as highly associated with poor prognosis was CENP-F, 
which encodes for a kinetochore-associated protein implicated in the regulation of cell 
division,16,17 S100A9, previously associated with inflammation and more recently with 
tumor development and metastasis,18-20 survivin, an inhibitor of apoptosis and mitotic 
regulator,21 cathepsin L2, a cysteine protease,22 BUB1, a checkpoint kinase regulating the 
anaphase promoting complex or cyclosome,23 carbonic anhydrase IX, a hypoxia-regulated 
enzyme involved in tumor cell survival,24 a neuropeptide, CART25 and adrenomedullin, an 
angiogenic peptide.26 Genes we identified as being highly associated with good prognosis 
included ER, PR, keratin 18, and serpinA3, a protease inhibitor,27 as well as lipophilin B and 
mammaglobin A, which form a heterodimeric complex and are overexpressed in breast 
cancer, but whose function remains unknown.28,29 A heatmap was generated that depicts the 
association of the prognostic genes we identified, with their respective class (Fig. 2). Her2 
expression was not a predictor of outcome in our re-analysis and ranked half way through 
the 5,000 significant genes in the dataset analysed (data not shown).
CENP-F is associated with poor prognosis in a related primary breast cancer DNA 
microarray dataset
CENP-F ranked 66 out of 100 genes associated with poor prognosis, with only small 
differences in correlation with survival between genes. We analyzed the expression of 
CENP-F in a related primary breast cancer DNA microarray dataset derived from 295 breast 
tumors.5 Tumor samples were classified according to CENP-F mRNA expression based on 
absolute expression analysis P values (alpha level of 0.05), following the method used by 
Moody et al.7 We found that CENP-F mRNA was overexpressed in 63 (21%) of the 295 
tumors, with 108 tumors showing decreased expression and 124 tumors had no change in 
expression, relative to reference RNA. High CENP-F expression was associated with 
increased tumor size (p = 0.028), high tumor grade (p < 0.001) and ER-negative tumors (p < 
0.001) (Table I). In addition, CENP-F mRNA expression was related significantly to reduced 
overall survival (p < 0.001) and reduced metastasis-free survival (p < 0.001) (Fig. 3).
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Expression of CENP-F in primary breast cancer
Our next aim was to validate our findings using CENP-F expression at the protein level. The 
specificity of the anti-CENP-F antibody was first established using Western blotting, in 
parallel with immunohistochemical analysis of formalin-fixed, paraffin-embedded cell lines 
mimicking the handling of the primary tumors. CENP-F is maximally expressed in the 
G2/M phase of the cell cycle.16,17 Each of the 4 breast cancer cell lines used in the study 
were treated with the anti-mitotic agent, nocodazole, which arrests cells at the G2/M phase 
of the cell cycle. As shown in Figure 4a, the anti-CENP-F antibody detected a protein of 
~350 kDa by Western blotting, with M-phase arrested, nocodazole-treated cells showing 
increased CENP-F expression when compared with untreated cells, as expected. Nuclear 
expression of CENP-F was detected by immunohistochemistry in a proportion of cells in 
each of the cell lines examined, in the absence of nocodazole (Fig. 4b).
CENP-F expression was then assessed in 2 different breast cancer cohorts (I and II) arranged 
in TMAs. For breast cancer cohort I, 90 (99%) out of 91 tumors available for analysis, 
expressed nuclear CENP-F in various amounts (Fig. 5). In cohort II, 289 samples were 
available for analysis and nuclear staining was seen in 206 (71%) out of 289 specimens. 
Patients from cohort I were significantly younger (p = 0.007) and tumor size was 
significantly larger (p = 0.006) than samples available for analysis from cohort II, which 
could contribute to the differences in the proportion of CENP-F-positive tumors between the 
cohorts. In addition, cohort I included, more ER negative breast carcinomas compared to 
cohort II, 29% versus 20%, but this difference was not statistically significant. There was no 
significant difference in grade, nodal status or PR status between the samples analyzed in 
cohorts I and II.
CENP-F protein expression correlates with clinico-pathological parameters in primary 
breast cancer
In patient cohorts I and II, we analyzed potential associations between CENP-F expression 
and known clinico-pathological parameters such as tumor size, tumor type, grade, hormone 
receptor status, patient age and the presence of lymph node metastases. We used a 10% cut-
off point for CENP-F expression to categorize samples into groups, in accordance with 
previous studies.10 CENP-F expression was associated with ER-negative tumors (p = 0.028) 
in cohort II, and with high grade tumors in both cohort I (p = 0.002) and cohort II (p < 
0.001) (Table II). CENP-F expression was not associated with tumor size, patient age, lymph 
node status, histological type or PR status in either cohort.
CENP-F protein expression correlates with tumour biological parameters in primary breast 
cancer
CENP-F expression was associated with the proliferation marker Ki67 in cohort II (Table 
III; p < 0.001) but not in cohort I (Table III; p = 0.198). In addition, CENP-F expression was 
associated with markers of chromosomal instability (CIN) including cyclin E overexpression 
(p = 0.021), survivin nuclear expression (unpublished data; p = 0.001), c-Myc amplification 
(p = 0.003), increased telomerase activity (p = 0.002) and aneuploidy (p = 0.025) in cohort I, 
indicating a link between CENP-F and CIN in these tumors (Table III). VEGF-A was not 
associated with CENP-F expression in either cohort I (p = 0.070) or cohort II (p = 0.959). 
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However, in cohort II, significant associations were observed between CENP-F expression 
and tumor-specific VEGFR2 expression (p = 0.001) and phosphorylated Ets-2 (p = 0.001) 
but not with phosphorylated Erk1/2 (p = 0.190) (Table III). Finally, we found no association 
between CENP-F expression and tumor specific VEGFR1, p53 or Her2 overexpression 
(Tables II and III).
CENP-F protein expression correlates with clinical outcome in primary breast cancer
Clinical follow-up data were available for all patients in cohorts I and II.8 Patient cohorts 
were analyzed separately. In agreement with previous findings,10 we found that using a cut-
off of 10% CENP-F expression best separated patients on the basis of survival. In cohort I, 
CENP-F expression showed a significant association with overall survival (p = 0.05; Fig. 
6a). In cohort II, expression of CENP-F correlated significantly with both breast cancer 
specific survival (p = 0.009) and overall survival (p = 0.04) (Fig. 6b and 6c).
Patients from cohort I had overall survival information only, and patient numbers were too 
low to carry out multivariate Cox regression analysis. In a univariate analysis of cohort I, 
CENP-F expression was associated with worse overall survival, with this association 
approaching significance (HR, 2.03; 95% CI, 0.97–4.24; p = 0.059). Univariate and 
multivariate Cox regression analyses were conducted on cohort II (Table IV). CENP-F 
expression, ER and tumor size were all significantly associated with breast cancer-specific 
survival (p = 0.011; 0.006; 0.001, respectively) but patient age, VEGFR2 and phospho-Ets-2 
were not (p = 0.088; 0.408 and 0.544, respectively). In a multivariate analysis including ER 
and tumor size, CENP-F expression was an independent predictor of breast cancer-specific 
survival (p = 0.036) (Table IV). Tumor grade was not included in the multivariate model as 
our data suggests that CENP-F is involved in CIN; thus, tumor grade may be on a causal 
pathway between CENP-F and survival and should, therefore, not be included in 
multivariate models with CENP-F.30,31 Using a similar approach, we carried out univariate 
analysis for overall survival on CENP-F expression, ER, VEGFR2, phospho-Ets-2, tumor 
size and patient age (Table V). CENP-F expression, tumor size and patient age were 
significantly associated with overall survival in a univariate analysis (p = 0.047; <0.001; 
<0.001, respectively), and in a multivariate analysis CENP-F retained its prognostic 
significance (p = 0.040) together with patient age (p < 0.001) (Table V). Ki67 showed only 
borderline significant association with overall survival in cohort II (p = 0.05) and was not 
significant when added to multivariate models for breast cancer specific or overall survival 
(data not shown).
Discussion
DNA microarrays offer new possibilities for the elucidation of individual genes and groups 
of genes that are preferentially expressed in tumor subgroups. The 70-gene prognosis 
classifier identified by van’t Veer et al.1 contained a large number of unknown or unexpected 
genes and none of the well-known prognostic markers in breast cancer such as ER, Her-2, 
uPA or PAI-1.32 This dataset forms the basis of a clinical trial, which aims to validate the 
efficacy of using the identified classifier for tailoring of treatment options. However, the 
methodology used to obtain this gene signature has been criticized.3,4
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Given the complexity of selecting a relatively small number of informative genes from the 
many thousands of genes represented on a DNA microarray, reanalysis of such data using 
alternative approaches to identify discriminating genes is warranted. Here, we used the 
statistical method of BGA, a powerful method for the analysis of cancer microarray data,6 to 
reanalyze this breast cancer dataset from van’t Veer et al.1 Our reanalysis approach revealed 
genes involved in key processes such as checkpoint control, apoptosis and angiogenesis, 
most of which were previously unidentified in the original analysis.
The classification accuracy we achieved using the same training and test samples as van’t 
Veer et al.1 was comparable to published results, i.e. 84%. However, when training and test 
samples were selected randomly, the classification accuracy varied widely from a maximum 
accuracy of 84% to as low as 36%, with a median classification accuracy of 68%. Similar 
findings have been published by others,3,4 suggesting a bias in the selection of the original 
training and test samples.
In our reanalysis of the van’t Veer dataset,1 CENP-F was among the genes that were highly 
associated with poor prognosis that could be studied at the protein level using TMAs. 
CENP-F is a cell cycle-regulated protein associated with kinetochores, the site at which 
chromosome-microtubule interactions are monitored and the source of checkpoint signals.33 
CENP-F is maximally expressed at the G2/M phase of the cell cycle16,17 and has been 
implicated in kinetochore assembly and/or the spindle checkpoint.34,35 More recently, 
CENP-F has been shown to play a central role in the recruitment of the checkpoint proteins, 
BubR1 and Mad1, resulting in a sustained checkpoint response.36
In a related DNA microarray dataset that we reanalyzed containing 295 breast tumor 
samples,5 over-expression of CENP-F mRNA was associated with larger tumor size, as well 
as ER-negative, high grade tumors. CENP-F mRNA expression correlated significantly with 
worse overall survival and a decreased probability of remaining metastasis-free.
Two different primary breast cancer cohorts were used to further investigate the role of 
CENP-F. Two cohorts were analyzed, as each cohort has unique data available. CENP-F 
protein expression correlated with reduced breast cancer-specific survival and overall 
survival in both univariate and multivariate analyses. The strong correlation between CENP-
F expression and breast cancer-specific survival highlights the usefulness of CENP-F as a 
breast cancer-specific marker of poor outcome. Our findings are in agreement with a 
previous report analyzing CENP-F expression and disease-free survival in node-negative 
breast cancer patients.10
In cohort I, parameters relating to cell cycle deregulation and CIN had previously been 
analyzed.14,37 CENP-F expression was associated with cyclin E over-expression, survivin 
nuclear expression and c-Myc amplification. Cyclin E is involved in centro-some duplication 
leading to CIN,38-40 while constitutive expression of cyclin E has been shown to result in 
CIN41,42 and is associated with poor prognosis in breast cancer.14 Survivin has been 
reported to activate the cyclin E/Cdk2 complex resulting in an accelerated S phase shift.43 
CENP-F expression was also associated with c-Myc amplification which has been shown to 
activate cyclin E/Cdk2, leading to cell cycle progression and proliferation.44 In addition, 
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CENP-F expression correlated significantly with high telomerase activity. Telomerase 
activation is associated with telomere dysfunction, a major mechanism underlying CIN of 
human cancer.45,46 Furthermore, a significant proportion of tumors over-expressing CENP-F 
were aneuploid, strengthening the relation between CENP-F expression and markers of CIN. 
Additional studies, including FISH analysis, will determine if these associations have 
functional significance. FISH analysis could not be performed in this study because of 
insufficient sample availability
While tumor VEGF-A expression did not correlate with CENP-F expression in either patient 
cohort I or II, we found a significant correlation between tumor cell VEGFR2 expression 
and CENP-F in cohort II. CENP-F is a phosphoprotein but it is not known which kinases 
target CENP-F for phosphorylation or the role of phosphorylation in CENP-F regulation. It 
is tempting to speculate that CENP-F may be a target for phosphorylation through cyclin E 
or VEGFR2, as CENP-F is significantly associated with expression of both of these proteins. 
However, further studies will need to be carried out to establish a functional link.
In line with other publications, CENP-F was associated with proliferation47-49 and ER 
negativity5,10 in cohort II. Furthermore, CENP-F expression was associated with the 
transcription factor phospho-Ets-2. Ets-2 expression in breast cancer may be linked to 
proliferation,8 however, the downstream target genes are unknown. CENP-F regulates gene 
transcription and proliferation through association with the transcription factor ATF4.50 Our 
results suggest that CENP-F may be a potential candidate for Ets-2 co-transcriptional 
regulation.
CENP-F is a farnesylated protein and is targeted by farnesyl transferase inhibitors 
(FTIs)51,52 resulting in CENP-F inactivation. Originally generated to inhibit oncogenic RAS, 
FTIs are effective anti-neoplastic agents. It is now becoming apparent that RAS is not the 
only target of FTIs; however, the role of other molecular targets and their mechanism of 
action remains elusive.53 FTIs have been shown to be effective in clinical trials of patients 
with metastatic breast carcinoma, especially in Her2 positive patients54,55 and CENP-F-
positive breast cancer has a pathologic response to preoperative chemotherapy.56 FTI-
sensitive cells pause at the G2/M phase of the cell cycle51,57 and have misaligned 
chromosomes,58 similar to cells depleted of CENP-F by RNAi.59,60 The anti-neoplastic 
activity, involving inhibition of proliferation and, apoptosis may be partly due to CENP-F 
inhibition. Thus CENP-F may be an important, clinically significant target in breast cancer 
and CENP-F farnesylation a useful biomarker of tumor response.
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BGA between group analysis
CENP-F centromere protein F
CIN chromosomal instability
ER oestrogen receptor
ERK 1/2 extracellular signal-regulated kinase 1/2
FCS foetal calf serum
FISH fluorescence in situ hybridization
GO gene ontology
Her2 human epidermal growth factor receptor 2
MMP-9 matrix metalloproteinase-9
PAI-1 plasminogen activator inhibitor 1
TMA tissue microarray
uPA urokinase plasminogen activator
VEGF-A vascular endothelial growth factor-A
VEGFR1 vascular endothelial growth factor receptor 1
VEGFR2 vascular endothelial growth factor receptor 2
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Histogram of percent classification accuracy using randomly selected training and test 
samples. BGA was applied iteratively on 96 samples that were randomly split 100 times into 
77 training and 19 test samples. The accuracy of the classification of the test samples was 
recorded at each iteration and plotted on a graph. The training and test data contained 5,000 
genes in each case.
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Heatmap of top 100 genes associated with good prognosis and the top 100 genes associated 
with poor prognosis. Each row represents a tumor and each column a gene transcript. PGR = 
the HUGO gene symbol for the progesterone receptor, ESR1 = the HUGO gene symbol for 
the oestrogen receptor. The colour bar is in a log10 scale. Tumours and genes are clustered 
according to expression levels. Hierarchical clustering analysis was performed using average 
linkage and the Euclidean distance metric.
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Kaplan-Meier analysis of (a) overall survival and (b) metastasis-free survival of 295 patients 
from the van de Vijver study. Patients are stratified on the basis of low or high CENP-F 
expression, as previously measured by DNA microarray analysis.
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Validation of the anti-CENP-F antibody using Western blotting and immunohistochemistry. 
(a) Protein extracts from T47D, SK-BR3, BT474, and MDA-MB-231 cells gave a single 
distinct band of approximately 350 kDa via Western blot analysis. (b) CENP-F was 
expressed in a proportion of cells in each of the cell lines examined by 
immunohistochemistry, in the absence of nocodazole. Syn = cells synchronised at mitosis 
using the mitotic inhibitor, nocodazole.
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A breast cancer TMA stained immunohistochemically with the anti-CENP-F antibody. 
CENP-F expression is indicated by brown staining. Nuclear staining of different intensities 
and fractions were observed only in tumor cells.
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Kaplan-Meier analysis of patients with invasive breast cancer stratified by CENP-F 
expression. (a) Overall survival of 91 patients from cohort I, (b) overall survival of 261 
patients from cohort II and (c) breast cancer-specific survival in 261 patients from cohort II. 
A cut-off point of 10% positive nuclei was used. The P values were calculated using the log-
rank test.
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TABLE I
ASSOCIATION BETWEEN CENP-F EXPRESSION IN THE VAN DE VIJVER DNA MICROARRAY 
DATASET, AND CLINICOPATHOLOGICAL PARAMETERS
Variable CENP-F (negative/low) (n = 108) CENP-F (high) (n = 63) P value (χ2 test)
Age
 Median (range) 43 (32–52) 45 (26–52)
 <Median (26–44) 49 (45) 33 (52) 0.376
 >Median (44–53) 59 (55) 30 (48)
Tumor size (mm)
 Median (range) 20 (2–0) 23 (10–2)
 T1 (1–20) 65 (60) 27 (43) 0.028
 T2 (>20) 43 (40) 36 (57)
NHG1
 1 45 (42) 6 (10) <0.001
 2 38 (35) 18 (29)
 3 25 (23) 29 (61)
Lymph-node status
 Negative 65 (60) 35 (56) 0.553
 Positive 43 (40) 28 (44)
ER status
 ER− 13 (12) 25 (40) <0.001
 ER+ 95 (88) 38 (60)
CENP-F expression levels were unchanged in 124 tumors.
1
NHG = Nottingham histological grade.
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TABLE III
ASSOCIATION BETWEEN TUMOUR BIOLOGICAL PARAMETERS AND CENP-F EXPRESSION IN 
COHORTS I AND II
Variable (n) CENP-F <10% CENP-F ≥10% p value
Cohort I
VEGF-A1 (89) 0.0702
 Low 5 (14) 3 (5.6)
 Intermediate 23 (66) 29 (53.7)
 High 7 (20) 22 (40.7)
Cyclin E3 (91) 0.0212
 Low 29 (83) 33 (59)
 High 6 (17) 23 (41)
Telomerase activity4 (86) 0.0025
 Median 0.81 3
 Range 0–54.7 0–153
Myc amplification6 (71) 0.0037
 Low 27 (96) 29 (67)
 Intermediate/High 1 (4) 14 (33)
Ploidy (85) 0.0257
 Diploid 19 (61) 19 (35)
 Aneuploid 12 (39) 35 (65)
Survivin-nuclear1 (91) 0.0017
 Negative 7 (20) 5 (9)
 <50% 22 (63) 21 (37.5)
 >50% 6 (17) 30 (53.5)
Her26 (88) 0.4232
 Grade 0–2 29 (85) 42 (78)
 Grade 3 5 (15) 12 (22)
 p53 status1 (89) 0.0952
 p53 − 27 (82) 36 (64)
 p53 + 6 (18) 20 (36)
Ki671 (89) 0.1982
 ≤10% 11 (32) 10 (18)
 >10% 23 (68) 45 (82)
Cohort II
VEGFR21 (238) 0.0017
 Neg/ Low 76 (50) 23 (26)
 Intermediate 55 (37) 44 (51)
 High 20 (13) 20 (23)
VEGF-A1 (235) 0.9597
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Variable (n) CENP-F <10% CENP-F ≥10% p value
 Neg/Low 54 (37) 35 (39)
 Intermediate 65 (44.5) 35 (39)
 High 27 (18.5) 19 (22)
VEGFR11 (275) 0.3387
 Neg/Low 28 (16) 15 (15)
 Intermediate 75 (42) 34 (35)
 High 74 (42) 49 (50)
Phospho-Ets-21 (240) 0.0017
 Negative 59 (37) 18 (18)
 Low 43 (27) 34 (35)
 Intermediate 41 (26) 24 (25)
 High 15 (10) 22 (22)
Phospho-Erk 1/21 (231) 0.1907
 Negative 66 (43) 32 (35.5)
 Low 43 (28) 17(30)
 Intermediate 29 (19) 13 (19)
 High 16 (10) 14 (15.5)
Ki671 (260) <0.0017
 ≤10% 76 (42) 15 (15)
 >10% 106 (58) 83 (85)






Measured by Western blotting and densitometry.
4




Measured by fluorescence in situ hybridisation.
7
Chi-square test for trend.
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